• Abivax flagged seven obefazimod abstracts for ulcerative colitis, scheduled for presentation at UEG Week 2026 on Oct. 17-20.
• The disclosures include Phase 3 ABTECT maintenance results, intended to reinforce the drug’s efficacy and safety profile in moderate-to-severe disease.
• Additional updates cover Phase 3 induction analyses, longer-term Phase 2 follow-up, and preclinical work suggesting anti-fibrotic activity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2408286_en) on September 30, 2026, and is solely responsible for the information contained therein.